Press releases

Company expands market-leading family of neurovascular stents

"I am proud of the way the organization executed in a number of key areas during the quarter," said Ray Elliott, President and CEO

Trial data to help develop a clinical alert that identifies the early onset of worsening heart failure

Company to webcast its conference call with Q2 2010 financial results and business highlights on July 21

Two new splitters allow multi-site placement of up to four spinal cord stimulation leads

Refinancing to help strengthen Company’s capital structure and provide enhanced capacity to fund acquisitions and other investments in technologies

Longer balloons provide physicians more options for treating peripheral artery disease

Women experienced a 70 percent reduction in heart failure events compared to a 35 percent reduction for men

Company to participate in the healthcare conference on June 24 in Boston; live webcast and replay will be available

Presentations to include results of the MADIT-CRT trial and the ALTITUDE clinical science program

CE Mark approval includes specific indication for treatment of diabetic patients

Company to participate in the June 16th conference in Los Angeles; live webcast and replay will be available

Randomized study of nearly 3,000 patients to evaluate Company's third-generation drug-eluting stent technology

Next-generation balloon catheter technology catheter developed specifically to address physicians' needs in optimizing coronary stent deployment

Company's iLab® Ultrasound Imaging System compatible with leading X-ray systems

Presentations to include analyses from SYNTAX trial, as well as clinical data supporting the performance of drug-eluting stents

Company expands Sterling line of peripheral angioplasty balloon catheters to include long balloons designed for below-the-knee procedures

Next-generation system strengthens Company's endometrial ablation portfolio for the treatment of menorrhagia

ACUITY Break-Away™ Lead Delivery System designed to place leads in veins of varying sizes, including difficult-to-access veins

Approval includes specific indication for treatment of diabetic patients

Upgrade provides enhanced functionality, including the ability to view an expanded history of a patient's remote follow-up data

Presentations will provide new insights for physicians who treat patients with implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds)

Results of study using Boston Scientific's WallFlex® Duodenal Stent presented at Digestive Disease Week®

EVIDENCE Trial to study Boston Scientific's Precision Plus™ Spinal Cord Stimulator System

Positive results to be presented for SpyGlass® Direct Visualization System, Radial Jaw® 4 Biopsy Forceps and WallFlex® Duodenal Stents